European Journal of Cancer
Volume 41, Issue 6 , Pages 888-907 , April 2005

Surgical management of prostate cancer: Advances based on a rational approach to the data

  • Anoop M. Meraney

      Affiliations

    • Glickman Urological Institute A-100, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    • ,
  • Alexander Haese

      Affiliations

    • Department of Urology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Jüri Palisaar

      Affiliations

    • Department of Urology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Markus Graefen

      Affiliations

    • Department of Urology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Thomas Steuber

      Affiliations

    • Department of Urology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Hartwig Huland

      Affiliations

    • Department of Urology, University Clinic Hamburg-Eppendorf, Hamburg, Germany
    • ,
  • Eric A. Klein

      Affiliations

    • Glickman Urological Institute A-100, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    • Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 216 444 5591; fax: +1 216 445 3532

Received 9 January 2005 ,Revised 8 February 2005 ,Accepted 8 February 2005.

References 

  1. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897–906
  2. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994;151:1571–1574
  3. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71–74(discussion 74–75)
  4. Stamey TA. Making the most out of six systematic sextant biopsies. Urology. 1995;45:2–12
  5. Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it. J Urol. 1995;153:1496–1498
  6. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980
  7. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161
  8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific an tigen level < or = 4.0ng per milliliter. N Engl J Med. 2004;350:2239–2246
  9. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289–294
  10. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with RP. J Urol. 1988;139:766–772
  11. Hoekx L, Jeuris W, Van Marck E, et al. Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation. Acta Urol Belg. 1998;66:1–2
  12. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747–752
  13. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. RP treated patients. J Urol. 1989;141:1076–1083
  14. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–954
  15. Oesterling JE. Age-specific reference ranges for serum PSA. N Engl J Med. 1996;335:345–346
  16. Partin AW, Criley SR, Subong EN, et al. Standard versus age-specific prostate-specific antigen reference ranges among men with clinically localized prostate cancer: a pathological analysis. J Urol. 1996;155:1336
  17. Reissigl A, Pointner J, Horniger W, et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology. 1995;46:662
  18. Littrup PJ, Kane RA, Mettlin C, et al. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Cancer. 1994;74:3146
  19. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817–821
  20. Catalona WJ, Richie JP, de Kernion JB, et al. Comparison of prostate-specific antigen concentration versus prostate-specific antigen density in the early detection of prostate cancer: receiver operator characteristic curves. J Urol. 1994;152:2031
  21. Brawer MK, Aramburu EAG, Chen GL, et al. The inability of prostate-specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol. 1993;150:369
  22. Djavan B, Zlotta AR, Byttebier G, et al. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol. 1998;160:411–418(discussion 418–419)
  23. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am. 1993;20:665–670
  24. Carter HB, Pearson JD, Metter EJ, et al. longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215–2220
  25. Nixon RG, Wener MH, Smith KMB. Biological variation of prostate specific antigen levels in serum: an evaluation of day-to-day physiological fluctuations in a well-defined cohort of 24 patients. J Urol. 1997;157:2183–2190
  26. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37:1618–1625
  27. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222–226
  28. Luderer AA, Chen YT, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995;46:187–194
  29. Prestigiacomo AF, Lilja H, Pettersson K, et al. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol. 1996;156:350–354
  30. Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100–105
  31. Carter HB, Partin AW, Luderer AA, et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 1997;49:379–384
  32. Haese A, Graefen M, Noldus J, et al. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol. 1997;158:2188–2192
  33. Partin AW, Catalona WJ, Southwick PC, et al. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996;48:55–61
  34. Park S, Shinohara K, Grossfeld GD, et al. Prostate cancer detection in men with prior high grade prostatic intraepithelial neoplasia or atypical prostate biopsy. J Urol. 2001;165:1409–1414
  35. Davidson D, Bostwick DG, Qian J, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol. 1995;154:1295–1299
  36. Raviv G, Zlotta AR, Janssen T, et al. Do prostate specific antigen and prostate specific antigen density enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma. Cancer. 1996;77:2103–2108
  37. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–1290
  38. Cooner WH, Mosley BR, Rutherford CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146–1152(discussion 1152–1144)
  39. Ellis WJ, Chetner MP, Preston SD, et al. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol. 1994;152:1520–1525
  40. Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol Int. 1997;59:239–242
  41. Gore JL, Shariat SF, Miles BJ, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165:1554–1559
  42. Uzzo RG, Wei JT, Waldbaum RS, et al. The influence of prostate size on cancer detection. Urology. 1995;46:831–836
  43. Karakiewicz PI, Hanley JA, Bazinet M. Three-dimensional computer-assisted analysis of sector biopsy of the prostate. Urology. 1998;52:208–212
  44. Djavan B, Remzi M, Marberger M. When to biopsy and when to stop biopsying. Urol Clin North Am. 2003;30:253–262viii
  45. Djavan B, Remzi M, Schulman CC, et al. Repeat prostate biopsy: who, how and when? A review. Eur Urol. 2002;42:93–103
  46. Stewart CS, Leibovich BC, Weaver AL, et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166:86–91(discussion 91–82)
  47. American Joint Committee on Cancer. Prostate. In: AJCC Cancer Staging Manual, 6th edn, 2002, pp. 309–316
  48. Ohori M, Kattan MW, Utsunomiya T, et al. Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible. J Urol. 2003;169(3):964–968
  49. Augustin H, Graefen M, Palisaar J, et al. Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging. J Clin Oncol. 2003;21(15):2860–2868
  50. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology. 1995;45(1):70–74
  51. Graefen M, Haese A, Pichlmeier U, et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing RP. J Urol. 2001;165(3):857–863
  52. Cagiannos I, Graefen M, Karakiewicz PI, et al. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement. J Clin Oncol. 2002;20(8):2025–2030
  53. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445–1451
  54. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843–848
  55. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170(5):1798–1803
  56. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following RP for prostate cancer. J Natl Cancer Inst. 1998;90(10):766–767
  57. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after RP. J Clin Oncol. 2002;20(15):3206–3212
  58. Onur R, Littrup PJ, Pontes JE, et al. Contemporary impact of transrectal ultrasound lesions for prostate cancer detection. J Urol. 2004;172(2):512–514
  59. Rifkin MD, Zerhouni EA, Gatsonis CA, et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med. 1990;323(10):621–626
  60. Wolf JS, Cher M, Dall’era M, et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before RP. J Urol. 1995;153(3 Pt 2):993–999
  61. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171(6 Pt 1):2122–2127
  62. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing RP: high incidence of lymph node metastasis. J Urol. 2002;167(4):1681–1686
  63. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after RP and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781–1788
  64. Millin T. Retropubic Urinary Surgery. London: Livingstone; 1947;
  65. Reiner WG, Walsh PC. J Urol. 1979;
  66. Walsh PC, Donker PJ. J Urol. 1982;
  67. Shir Y, Raja SN, Frank SM, Brendler CB. Intraoperative blood loss during radical retropubic prostatectomy: epidural versus general anesthesia. Urology. 1995;45(6):993–999
  68. Walsh PC. Anatomic radical retropubic prostatectomy. In:  Walsh PC,  Retick AB,  Vaughan ED,  Wein AJ editor. Campbell’s Urology. Philadelphia: Saunders; 2002;p. 3107–3129
  69. Shir Y, Frank SM, Brendler CB, et al. Postoperative morbidity is similar in patients anesthetized with epidural and general anesthesia for RP. Urology. 1994;44(2):232–236
  70. Lepor H, Nieder AM, Ferrandino MN. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol. 2001;166(5):1729–1733
  71. Dillioglugil O, Leibman BD, Leibman NS, et al. Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 1997;157(5):1760–1767
  72. Leandri P, Rossignol G, Gautier JR, et al. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urol. 1992;147:883–887
  73. Chang SS, Duong DT, Wells N, et al. Predicting blood loss and transfusion requirements during RP: the significant negative impact of increasing body mass index. J Urol. 2004;171(5):1861–1865
  74. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996;334(26):1685–1690
  75. Chun TY, Martine S, Lepor H. Preoperative recombinant erythropoietin versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology. 1997;50:727–732
  76. Lepor H. Practical consideration in radical retropubic prostatectomy: Lepor H. Urol Clin N Amer. 2003;30:363–368
  77. Monk T, Goodnough LT, Brecher ME, et al. A Prospective randomized comparison of three blood conservation strategies for RP. Anesthesiology. 1999;91:24–33
  78. Lepor H. Radical retropubic prostatectomy. UCNA. 2001;28:509–519
  79. Davis JW, Schellhammer PF. Radical retropubic prostatectomy. In: Prostate Cancer. London: Academic Press; 2003;p. 279–287
  80. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after RP. N Engl J Med. 2002;346(15):1138–1144
  81. Klein EA, Kupelian PA, Tuason L, et al. Initial dissection of the lateral fascia reduces the positive margin rate in RP. Urology. 1998;51(5):766–773
  82. Campbell EW. Total prostatectomy with preliminary ligation of the vascular pedicles. J Urol. 1959;81:464
  83. Akduman B, Crawford ED. RP: the retropubic antegrade approach. In:  Mydlo JH,  Godec CJ editor. Prostate Cancer Science and Clinical Application. London: Academic Press; 2003;p. 301–309
  84. Korman HJ, Watson RB, Civantos F, et al. RP: is complete resection of the seminal vesicles really necessary. J Urol. 1996;156(3):1081–1083
  85. D’Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostatic specific antigen failure after RP for prostate cancer. J Urol. 1995;154:131
  86. Tefilli MV, Gheiler EL, Tiguert R, et al. Prognostic indicators in patients with seminal vesicle involvement following RP for clinically localized prostate cancer. J Urol. 1998;160:802
  87. Selli C, De Antoni P, Moro U, et al. Role of bladder neck preservation in urinary continence following radical retropubic prostatectomy. Scand J Urol Nephrol. 2004;38(1):32–37
  88. Bianco FJ, Grignon DJ, Sakr WA, et al. RP with bladder neck preservation: impact of a positive margin. Eur Urol. 2003;43(5):461–466
  89. Srougi M, Nesrallah LJ, Kauffmann JR, et al. Urinary continence and pathological outcome after bladder neck preservation during radical retropubic prostatectomy: a randomized prospective trial. J Urol. 2001;165(3):815–818
  90. Steiner MS, Burnett AL, Brooks JD, et al. Tubularized neourethra following radical retropubic prostatectomy. J Urol. 1993;150:407–409(discussion 409–410)
  91. Beck PH, McAninch JW, Stutzman RE. Anterior bladder tube flap reconstruction of the urethrovesical neck after radical retropubic prostatectomy. J Urol. 1979;121:379–381
  92. Klotz L, Herschorn S. Early experience with intraoperative cavernous nerve stimulation with penile tumescence monitoring to improve nerve sparing during RP. Urology. 1998;52(4):537–542
  93. Holzbeierlein J, Peterson M, Smith JA. Variability of results of cavernous nerve stimulation during RP. J Urol. 2001;165(1):108–110
  94. Walsh PC, Marschke P, Catalona WJ, et al. Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during RP: a multi-institutional evaluation by experienced surgeons. Urology. 2001;57(3):491–494
  95. Quinlan DM, Nelson RJ, Walsh PC. Cavernous nerve grafts restore erectile function in denervated rats. J Urol. 1991;145(2):380–383
  96. Walsh PC. Nerve grafts are rarely necessary and are unlikely to improve sexual function in men undergoing anatomic RP. Urology. 2001;57(6):1020–1024
  97. Kim ED, Nath R, Kadmon D, et al. Bilateral nerve graft during radical retropubic prostatectomy: 1–year followup. J Urol. 2001;165:1950–1956
  98. Canto EI, Slawin KM. Sural nerve interposition graft during RP. In:  Mydlo J,  Godec CJ editor. Prostate Cancer Science and Clinical Practice. London: Academic Press; 2003;p. 289–300
  99. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152:1831–1836
  100. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol. 1998;160:2428–2434
  101. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110
  102. Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol. 1996;155:1361
  103. Kleer E, Oesterling JE. PSA and staging of localized prostate cancer. Urol Clin N Amer. 1993;20:695
  104. Shah O, Robbins DA, Melamed J, et al. The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy. J Urol. 2003;169(6):2147–2152
  105. Lepor H. Practical considerations in radical retropubic prostatectomy. Urol Clin N Amer. 2003;30(2):363–368
  106. Young HH. The early diagnosis and radical cure of carcinoma of the prostate: being a study of 40 cases and presentation of a radical operation which was carried out in four cases. Bull Johns Hopkins Hosp. 1905;16:315
  107. Belt E, Ebert CE, Surber AC. A new anatomic approach in perineal prostatectomy. J Urol. 1939;41:482
  108. Meraney AM, Gill IS. AUA Update Series. 2004;23:
  109. Hasan WA, Gill IS. Laparoscopic RP: current status. BJU Intl. 2004;94(1):7–11
  110. Guillonneau B, Vallancien G. Laparoscopic RP: initial experience and preliminary assessment after 65 operations. Prostate. 1999;39(1):71–75
  111. Bollens R, Vanden Bossche M, Roumeguere T, et al. Extraperitoneal laparoscopic RP. Results after 50 cases. Eur Urol. 2001;40(1):65–69
  112. Meraney AM, Gill IS. Robotic retropubic RP. In:  Mydlo J,  Godec CJ editor. Prostate Cancer Science and Clinical Practice. London: Academic Press; 2003;p. 371
  113. Ahlering TE, Skarecky D, Lee D, et al. Successful transfer of open surgical skills to a laparoscopic environment using a robotic interface: initial experience with laparoscopic RP. J Urol. 2003;170(5):1738–1741
  114. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol. 1999;162(2):433–438
  115. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152(5 Pt 2):1831–1836
  116. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after RP for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354–360
  117. Weldon VE, Tavel FR, Neuwirth H. Continence, potency and morbidity after radical perineal prostatectomy. J Urol. 1997;158(4):1470–1475
  118. Ruiz-Deya G, Davis R, Srivastav SK, et al. Outpatient RP: impact of standard perineal approach on patient outcome. J Urol. 2001;166(2):581–586
  119. Frazier HA, Robertson JE, Paulson DF. Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. J Urology. 1992;147:888–890
  120. Lerner SE, Fleischmann J, Taub HC, et al. Combined laparoscopic pelvic lymph node dissection and modified belt radical perineal prostatectomy for localized prostatic adenocarcinoma. Urology. 1994;43(4):493–498
  121. Salomon L, Anastasiadis AG, Katz R, et al. Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. European Urology. 2002;42(4):338–343
  122. Turk I, Deger S, Winkelmann B, et al. Laparoscopic RP. Technical aspects and experience with 125 cases. Eur Urol. 2001;40(1):46–52(discussion 53)
  123. Rassweiler J, Sentker L, Seemann O, et al. Laparoscopic RP with the Heilbronn technique: an analysis of the first 180 cases. J Urol. 2001;166(6):2101–2108
  124. Guillonneau B, Vallancien G. Laparoscopic RP: the Montsouris experience. J Urol. 2000;163(2):418–422
  125. Hu JC, Elkin EP, Pasta DJ, et al. Predicting quality of life after RP: results from CaPSURE. J Urol. 2004;171:703–707(discussion 707–708)
  126. Pietrow PK, Parekh DJ, Smith JA, et al. Health related quality of life assessment after RP in men with prostate specific antigen only recurrence. J Urol. 2001;166(6):2286–2290
  127. Yang BK, Young MD, Calingaert B, et al. Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. J Urol. 2004;172(1):264–268
  128. Hara I, Kawabata G, Miyake H, et al. Comparison of quality of life following laparoscopic and open prostatectomy for prostate cancer. J Urol. 2003;169(6):2045–2048
  129. Eastham JA, Scardino PT. RP. In:  Walsh PC,  Retick AB,  Vaughan ED,  Wein AJ editor. Campbell’s Urology. Philadelphia: Saunders; 2002;p. 3099
  130. Han M, Partin AW, Pound CR, et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin N Amer. 2001;28(3):555–565
  131. Hull GW, Rabbani F, Abbas F, et al. Cancer control with RP alone in 1,000 consecutive patients. J Urol. 2002;167:528
  132. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of RP as treatment for clinical stage C (T3) prostate cancer. Urology. 1993;41:113
  133. Gerber GS, Thisted RA, Chodak GW, et al. Results of RP in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol. 1997;32:385
  134. van den Ouden D, Tribukait B, Blom JH, et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1993;150:400
  135. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after RP and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781
  136. Iverson P. Bicalutamide 150mg in addition to standard care in patients with early, non-metastatic prostate cancer: results from the SPCG-6 study at a median follow-up of 5.3 years. AUA 2004 (abstract 1181)
  137. Bentzen SM, Tucker SL. Individualization of radiotherapy dose prescriptions by means of an in vitro radiosensitivity assay. Radiother Oncol. 1998;46:216
  138. Ohori M, Wheeler TM, Kattan MW, et al. Prognostic significance of positive surgical margins in RP specimens. J Urol. 1995;154:1818
  139. Davis BJ, Pisansky TM, Leibovich BC. Adjuvant external radiation therapy following RP for node-negative prostate cancer. Curr Opin Urol. 2003;13:117
  140. Bolla M, Van Poppel H, Van Cangh P, et al. Does postoperative radiotherapy after RP improve progression-free survival in pT3N0 prostate cancer. Proc Am Soc Clin Oncol. 2004;23:382
  141. Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology. 2003;62(suppl. 1):46–54
  142. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;791–794
  143. Paul R, Van Randenborgh H, Kubler H, et al. Significance of neoadjuvant therapy before RP. Urologe A. 2004;43:680
  144. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by RP: feasibility and preliminary results. J Clin Oncol. 2000;18:1050
  145. Clark PE, Peereboom DM, Dreicer R, et al. Phase II trial of neoadjuvant estramustine and etoposide plus RP for locally advanced prostate cancer. Urology. 2001;57:281
  146. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before RP for locally advanced prostate cancer. Urology. 2004;63:1138
  147. Oh WK, George DJ, Kaufman DS, et al. Neoadjuvant docetaxel followed by RP in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol. 2001;28:40
  148. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of RP after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol. 2004;171:709
  149. Russo P. Salvage RP after radiation therapy and brachytherapy. J Endourol. 2000;14(4):385–390
  150. Rogers E, Ohori M, Kassabian VS, et al. Salvage RP: outcome measured by serum prostate specific antigen levels. J Urol. 1995;153(1):104–110
  151. Shekarriz B, Upadhyay J, Pontes JE, et al. Urol Clin N Amer. 2001;28(3):545–553
  152. Neerhut GJ, Wheeler T, Cantini M, et al. Salvage RP for radiorecurrent adenocarcinoma of the prostate. J Urol. 1988;140(3):544–549
  153. Zincke H. RP and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcomes. J Urol. 1992;147:894–899
  154. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year follow up. J Urol. 1998;159(3):950–954discussion 954–955
  155. Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998;51(5):789–795
  156. Pontes JE, Montie J, Klein E, et al. Salvage surgery for radiation failure in prostate cancer. Cancer. 1993;71:976–980
  157. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) result after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urology. 1994;152:1850–1870
  158. Catalona WJ, Carvalhal GF, Mager DE, Smith DS. Potency, continence and complication rates in 1870 consecutive radical retropubic prostatectomies. J Urology. 1999;162(2):433–438
  159. Gillitzer R, Melchior SW, Hampel C, Wiesner C, Fichtner J, ThUroff JW. Specific complications of radical perineal prostatectomy: a single institution study of more than 600 cases. J Urology. 2004;172(1):124–128
  160. Gibbons RP, Correa RJ, Brannen GE, Mason JT. Total prostatectomy for localized prostatic cancer. J Urology. 1984;131(1):73–76
  161. Frazier HA, Robertson JE, Paulson DF. Radical prostatectomy: the pros and cons of the perineal versus retropubic approach. J Urology. 1992;147:888–890
  162. Haab F, Boccon-Gibod L, Delmas V, Boccon-Gibod L, Toublanc M. Perineal versus retropubic radical prostatectomy for T1, T2, prostate cancer. Br J Urology. 1994;74(5):626–629
  163. Lance RS, Freidrichs PA, Kane C, Powell CR, Pulos E, Moul JW, et al. A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer with the Uniformed Services Urology Research Group. BJU International. 2001;87(1):61–65
  164. Guillonneau B, Rozet F, Cathelineau X, Lay F, Barret E, Doublet JD, et al. Perioperative complications of laparoscopic radical prostatectomy: the Montsouris 3-year experience. J Urology. 2002;167(1):51–56
  165. Hoznek A, Salomon L, Olsson LE, Antiphon P, Saint F, Cicco A, et al. Laparoscopic radical prostatectomy. The creteil experience. Euro Urology. 2001;40(1):38–45
  166. Bhayani SB, Pavlovich CP, Hsu TS, Sullivan W, Su LM. Prospective comparison of short-term convalescence: laparoscopic radical prostatectomy versus open radical retropubic prostatectomy. Urology. 2003;61(3):612–616
  167. Roumeguere T, Bollens R, Vanden Bossche M, Rochet D, Bialek D, Hoffman P, et al. Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. World Journal of Urology. 2003;20(6):360–366
  168. Rassweiler J, Seemann O, Schulze M, Teber D, Hatzinger M, Frede T. Laparoscopic versus open radical prostatectomy: a comparative study at a single institution. J Urology. 2003;169(5):1689–1693
  169. Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB. Scardino PT. Risk factors for urinary incontinence after radical prostatectomy. J Urology. 1996;156(5):1707–1713
  170. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urology. 1994;152(5 Pt2):1831–1836
  171. Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000;283(3):354–360
  172. Leandri P, Rossignol G, Gautier JR, Ramon J. Radical retropubic prostatectomy: morbidity and quality of life. Experience with 620 consecutive cases. J Urology. 1992;147:883–887
  173. Bishoff JT, Motley G, Optenberg SA, Stein CR, Moon KA, Browning SM, et al. Incidence of fecal and urinary incontinence following radical perineal and rctropubic prostatectomy in a national population. J Urology. 1998;160(2):454–458
  174. Young MD, Weizer AZ, Silverstein AD, Crisci A, Albala DM, Vieweg J, et al. Urinary continence and quality of life in the first year after radical perineal prostatectomy. J Urology. 2003;170(6 Pt l):2374–2378

PII: S0959-8049(05)00145-0

doi: 10.1016/j.ejca.2005.02.005

European Journal of Cancer
Volume 41, Issue 6 , Pages 888-907 , April 2005

Article Tools

* Image Usage & Resolution